关键词: 甲巯丙脯酸, 阿魏酸钠, 高血压, 血管紧张素转化酶, 血栓素 A₂

Abstract: Angiotensin converting enzyme(ACE)inhibitor,Captapril(CAP),is a potent antihy-pertensive agent.Some reports suggest that CAP stimulates TXA₂ synthesis in the patients with essential hypertension.Sodium ferulate(SF)inhibits TXA₂ synthesis.In present study, the influence of SF on hypotensive effect and urinary exceretion of TXB₂(a stable metabolite of TXA₂)after CAP was observed in 44 patients with essential hypertension.A single oral dose of CAP(50 mg)decreased mean arterial pressure (from 16.25+0.85 to 13.65+1.1.14 kPa,n=28,P<0.01)and increased urinary TXB₂ excretion significantly(from 119.12+ 57.12 to 183.32+78.61 pg/min,n=16,P<0.05).The administration of SF 300 mg/day for one day did not affect the mean arterial pressure.CAP in combination with SF induced a decrease both in mean arterial pressure(from 16.33+1.14 to 13.83+1.77 kPa,n=16,P< 0.01)and urinary TXB₂ excretion(from 155.89+69.64 to 133.43+60.01 pg/min,n=16, P>0.05),though the latter was not so significant.Compared with the administration of CAP alone,the combination of CAP and SF induced stronger hypotensive effect(P<0.05) and the increased urinary TXB₂ excretion could be inhibited by SF.But the inhibition to ACE was the same.These results suggested that the increased urinary TXB₂ excretion by CAP can be inhibited and the hypotensive effect of CAP is potentiated by SF in essential hy-pertensive patients.

Key words: captapril sodium ferulate, Hypertension, Angiotensin converting enzyme, Thromboxin A2